Insiders who reported open-market trades in the last 12 months at the companies Jason P. Rhodes files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Dirk Kersten - $38.57M in DYN purchases and sales in the last 12 months
John Cox - $444K in DYN purchases and sales in the last 12 months
Brian S. Posner - $315K in DYN purchases and sales in the last 12 months
Douglas Kerr - $233K in DYN purchases and sales in the last 12 months
Erick Lucera - $229K in DYN purchases and sales in the last 12 months
Jason P. Rhodes is a corporate insider, tracked as Director of Dyne Therapeutics, Inc. (DYN). InsiderAlpha holds 10 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Jason P. Rhodes submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Jason P. Rhodes been buying or selling stock?
Recorded transactions: 0 open-market purchases and 75 open-market sales ($124.94M) across all tracked filings.
Jason P. Rhodes is Director of Dyne Therapeutics, Inc. (DYN). 10 SEC Form 4 filings on record going back to 2024, most recently on 17 August 2026. Most recent open-market trade: sold $8.06M of DYN on 17 August 2026. Lifetime open-market sales: $124.94M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Jason P. Rhodes.
InsiderAlpha's records for Jason P. Rhodes go back to 2024: 10 primary Form 4 filings, an average of 3.3 per year. 71 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
